<bill session="108" type="h" number="2968" updated="2013-07-14T19:01:54-04:00">
  <state datetime="2003-07-25">REFERRED</state>
  <status>
    <introduced datetime="2003-07-25"/>
  </status>
  <introduced datetime="2003-07-25"/>
  <titles>
    <title as="introduced" type="short">Biotechnology Future Investment Expansion Act of 2003</title>
    <title as="introduced" type="official">To permit biomedical research corporations to engage in certain equity financings without incurring limitations on net operating loss carryforwards and certain built-in losses, and for other purposes.</title>
  </titles>
  <sponsor id="400338"/>
  <cosponsors>
    <cosponsor id="400046" joined="2004-03-25"/>
    <cosponsor id="400058" joined="2004-02-04"/>
    <cosponsor id="400060" joined="2003-07-25"/>
    <cosponsor id="400064" joined="2003-07-25"/>
    <cosponsor id="400090" joined="2004-04-01"/>
    <cosponsor id="400098" joined="2004-05-05"/>
    <cosponsor id="400115" joined="2003-11-21"/>
    <cosponsor id="400123" joined="2003-09-23"/>
    <cosponsor id="400124" joined="2004-03-25"/>
    <cosponsor id="400133" joined="2004-06-03"/>
    <cosponsor id="400140" joined="2004-05-05"/>
    <cosponsor id="400154" joined="2004-05-05"/>
    <cosponsor id="400155" joined="2004-06-03"/>
    <cosponsor id="400161" joined="2004-05-05"/>
    <cosponsor id="400173" joined="2003-09-09"/>
    <cosponsor id="400176" joined="2004-03-18"/>
    <cosponsor id="400184" joined="2003-07-25"/>
    <cosponsor id="400194" joined="2003-09-09"/>
    <cosponsor id="400202" joined="2004-03-18"/>
    <cosponsor id="400228" joined="2004-05-12"/>
    <cosponsor id="400256" joined="2003-07-25"/>
    <cosponsor id="400265" joined="2003-09-23"/>
    <cosponsor id="400274" joined="2003-09-23"/>
    <cosponsor id="400285" joined="2003-09-23"/>
    <cosponsor id="400316" joined="2004-05-20"/>
    <cosponsor id="400324" joined="2003-11-18"/>
    <cosponsor id="400326" joined="2003-11-20"/>
    <cosponsor id="400367" joined="2004-05-05"/>
    <cosponsor id="400383" joined="2004-09-14"/>
    <cosponsor id="400415" joined="2004-05-05"/>
    <cosponsor id="400421" joined="2003-09-09"/>
  </cosponsors>
  <actions>
    <action state="REFERRED" datetime="2003-07-25">
      <text>Referred to the House Committee on Ways and Means.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSWM" name="House Ways and Means" activity="Referral, In Committee"/>
  </committees>
  <relatedbills>
    <bill relation="unknown" session="108" type="s" number="1773"/>
  </relatedbills>
  <subjects>
    <term name="Taxation"/>
    <term name="Accounting"/>
    <term name="Capital gains tax"/>
    <term name="Clinical trials"/>
    <term name="Commerce"/>
    <term name="Corporate debt"/>
    <term name="Corporate finance"/>
    <term name="Corporate reorganizations"/>
    <term name="Corporation taxes"/>
    <term name="Drug industry"/>
    <term name="Finance and financial sector"/>
    <term name="Health"/>
    <term name="Income tax"/>
    <term name="Investments"/>
    <term name="Losses"/>
    <term name="Pharmaceutical research"/>
    <term name="Science, technology, communications"/>
    <term name="Tax credits"/>
    <term name="Tax exclusion"/>
    <term name="Tax incentives"/>
  </subjects>
  <amendments/>
  <summary>7/25/2003--Introduced.
Biotechnology Future Investment Expansion Act of 2003 - Amends the Internal Revenue Code to provide that in the case of a biomedical research corporation, any owner shift involving a five-percent shareholder which occurs as the result of a qualified investment during the testing period shall be treated as occurring before the testing period. (Thus not counting toward net operating loss and tax credit carryover limitations.) Defines: (1) "biomedical research corporation" as a domestic corporation not in bankruptcy which has a drug or biologic in certain clinical trials; and (2) "qualified investment" as a stock acquisition in a biomedical research corporation acquired in cash at its original issue. Requires a biomedical research corporation to meet a five-year expenditure test with respect to any qualified investment.</summary>
</bill>
